JNJ-95475939

DRUG2 trials

Sponsors

Janssen Cilag International, Janssen Research & Development, LLC

Conditions

Dermatitis, AtopicModerate to Severe Atopic Dermatitis

Phase 2

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Active, not recruitingNCT06881251

Janssen Research & Development, LLCDermatitis, Atopic

Start: 2025-02-26End: 2026-03-26Updated: 2026-03-13

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis

Active, not recruitingCTIS2024-517814-13-00

Janssen Cilag InternationalModerate to Severe Atopic Dermatitis

Start: 2025-04-30Target: 86Updated: 2025-12-29